Safety of anti-TNF alpha therapy in children with juvenile idiopathic arthritis

L. Dekker, W. Armbrust, C.M.A. Rademaker, A.B.J. Prakken, W. Kuis, N.M. Wulffraat

Research output: Contribution to journalLiterature reviewpeer-review

Abstract

Anti-TNFalpha agents are frequently used in the treatment of severe JIA. Etanercept, a fully human soluble recombinant tumour necrosis factor p75 receptor Fc fusion protein, has been registered for the treatment of polyarticular course JIA patients who fail to respond to or do not tolerate methotrexate (MTX). Infliximab, a chimeric human-mouse monoclonal antibody to TNFalpha, is expected to be registered soon for JIA and Crohn's disease (CD) in children. As in adults, both agents are effective in controlling inflammation and inhibiting the progression of joint destruction. Despite this good clinical efficacy, the physician must remain alert for potential side effects, especially after prolonged use. This review gives an overview of the reported adverse events.

Original languageEnglish
Pages (from-to)252-258
Number of pages7
JournalClinical and Experimental Rheumatology
Volume22
Issue number2
Publication statusPublished - 2004

Keywords

  • TNF alpha
  • juvenile idiopathic arthritis
  • adverse effects
  • infections
  • tuberculosis
  • SYSTEMIC-LUPUS-ERYTHEMATOSUS
  • LONG-TERM EFFICACY
  • RHEUMATOID-ARTHRITIS
  • CROHNS-DISEASE
  • ETANERCEPT THERAPY
  • OPEN-LABEL
  • INFLIXIMAB
  • TUBERCULOSIS
  • ANTAGONISTS
  • ONSET

Fingerprint

Dive into the research topics of 'Safety of anti-TNF alpha therapy in children with juvenile idiopathic arthritis'. Together they form a unique fingerprint.

Cite this